Drugs / B12
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01719185 | Sep 2012 → Jan 2013 | hypertensive disorder, obesity disorder | Dr. Michael Lang | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00054938 | Mar 2003 → Dec 2005 | systemic lupus erythematosus | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05619328 | Sep 2022 → Nov 2023 | sensory peripheral neuropathy | Procter and Gamble | Completed | No outcome recorded |
| Phase 3 | NCT01371357 | May → Dec 2011 | hyperhomocysteinemia | Center for Health Sciences, Serbia | Completed | No outcome recorded |
| Phase 3 | NCT00170404 | Jun 2000 → Oct 2005 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05505006 | Mar 2021 → Aug 2024 | anemia, neoplasm | Azienda Ospedaliera Universitaria Integrata Verona | Unknown | No outcome recorded |
| Phase 4 | NCT00217178 | Jan 2000 → Oct 2005 | atherosclerosis | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06446830 | May 2024 → Nov 2025 overdue | — | Ain Shams University | Recruiting | No outcome recorded |
| — | NCT00018460 | Apr 1999 → Mar 2002 | cardiovascular disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT00806819 Comparator | Dec 2008 → Jun 2011 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | Met primary |
| Phase 4 | NCT03010579 Comparator | Oct 2016 → Dec 2017 | anemia, lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT01724476 Comparator | Dec 2014 → Mar 2017 | schizophrenia | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01921192 Comparator | Sep 2012 → Jul 2014 | proliferative diabetic retinopathy | University of Catania | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B12 | “2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid” NCT01371357 ↗12“The multivitamin for the intervention group has 5 ing folic acid, 1.7 mg B2, 100 mg B6, and I mg B12.” NCT00018460 ↗ “If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.” NCT03010579 ↗ “Vitamins B1 (100mg), B6 (100 mg), Plus B12 (5 mg) in Tablets” NCT05619328 ↗ “the tablet is a vitamin (B1, B6, B9, and B12).” NCT06446830 ↗ |
| Modality | Other / unclassified | “Vitamins: Folic acid, B6, B12” NCT00217178 ↗ |
| Route | Intramuscular | “receive weekly intramuscular injections of either 1000 mg B12 or Saline” NCT01719185 ↗ |